Work

Gene therapy in the treatment of familial hypercholesterolemia – Evaluation and development of viral vectors and gene transfer techniques (Geeniterapia familiaalisen hyperkolesterolemian hoidossa – Geenikuljettimien ja geeninsiirtomenetelmien kehittäminen ja arviointi)

Year: 2004
Type: dissertation
Abstract: Sustained production of therapeutic protein is fundamental for long-term amelioration of familial hypercholesterolemia (FH), an inherited autosomal disease caused by a mutation in the low-density lipoprotein receptor (LDLR) gene.Moloney murine leukemia virus (MMLV) -based retroviral vectors and lentiviral vectors are capable of integrating into the host cell genome which makes them an attractive tool for stable gene transfer.In this study we evaluated MMLV retroviral vectors and lentiviral vectors, based on human immunodeficiency virus -1 (HIV-1) and feline immunodeficiency virus (FIV), for their potential as gene delivery tools in conjunction with vascular ex vivo gene transfer and direct in vivo gene transfer to liver and brain.We developed an ex vivo gene transfer technique into rabbit arterial wall using autologous smooth muscle cells (SMCs) and demonstrated high efficiency local gene transfer in arteries.In addition to targeting local vascular phenomena during surgical procedures, we showed that genetically engineered SMCs can be used as a means of systemic delivery of gene products.Ex vivo gene therapy for liver disorders such as FH has proven laborious, time consuming and inefficient.In order to circumvent the adversity of ex vivo gene transfer and also the need for liver resection of standard MMLV-retroviral vectors, we generated HIV-1 -based lentiviral vectors encoding rabbit LDLR or green fluorescent protein under the control of a liver-specific promoter (LSP), and evaluated their efficacy and safety in vitro and in vivo.After demonstrating the functionality of the vectors in cell culture, we injected 1×10 9 infectious virus particles into the portal vein of Watanabe heritable hyperlipidemic (WHHL) rabbits.In addition, we injected another group of WHHL rabbits with MMLV retroviral vectors encoding for human LDLR (LTR-LDLR) or a marker gene.From liver biopsy and tissue samples we showed stable transgene expression and normal liver function and morphology with no sign of major infection or inflammatory changes.LSP-LDLR and LTR-LDLR treatment of WHHL rabbits had a therapeutic effect as it resulted in decreased cholesterol levels in comparison with the control rabbits.Furthermore, the rabbits treated with LDLR exhibited prolonged lifespan.Veterinarian pathological examination of the rabbits in all study groups revealed symptoms mainly related to atherosclerosis.No obvious gene transfer related pathological findings were detected.For improved vector safety, we constructed a doxycycline (Dox)-regulated self-inactivating HIV-1 lentiviral vector system.Following the verification of the system functionality in vitro, we assessed their applicability in vivo.We demonstrated that the dose-dependent and repeatedly inducible vector system was capable of efficient expression and explicit regulation of the transgene in rat brain in vivo.In conclusion, this study demonstrates the safety and potential usefulness of HIV-1 lentiviral vectors, and also of the standard MMLV-retroviral vectors, in the treatment of familial hypercholesterolemia. Constructing the vector systems towards targeted and regulated expression of a carefully chosen therapeutic gene from a distinct target organ, together with accurate choice of gene delivery approach, have beneficial effects on the safety and efficacy of gene therapy applications.
Language: Finnish
Subfield: Genetics
Open Access status: green
OpenAlex ID: W3095584148
Cites: 563
Cited by: 1
Related to: 9